| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,999,999 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 1 | $3M | 0 | $0 | $3M |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role …
Over the last 12 months, insiders at Inhibikase Therapeutics, Inc. have bought $3M and sold $0 worth of Inhibikase Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Inhibikase Therapeutics, Inc. have bought $1.92M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sands Capital Life Sciences Pulse Fund II, L.P. (10 percent owner) — $3M.
The last purchase of 2,068,965 shares for transaction amount of $3M was made by Sands Capital Life Sciences Pulse Fund II, L.P. (10 percent owner) on 2025‑11‑21.
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 2.07M 2.6795% | $1.45 | $3M | +23.49% | ||
| 2024-10-21 | Bellini Roberto | director | 1.46M 12.071% | $1.37 | $2M | -9.46% | ||
| 2024-10-21 | Munshi Amit | director | 365,000 3.0178% | $1.37 | $500,050 | -9.46% | ||
| 2024-10-21 | Kush Arvind | director | 145,000 1.1988% | $1.37 | $198,650 | -9.46% | ||
| 2022-08-16 | Werner Milton H. | President and CEO | 5,000 0.0198% | $0.80 | $4,000 | -18.09% | ||
| 2022-05-27 | Werner Milton H. | President and CEO | 5,000 0.0207% | $0.98 | $4,880 | -21.09% | ||
| 2022-05-20 | Werner Milton H. | President and CEO | 10,000 0.0362% | $0.60 | $6,000 | +14.09% | ||
| 2022-05-19 | FRATTAROLI JOSEPH | Chief Financial Officer | 3,948 0.016% | $0.64 | $2,543 | +18.78% | ||
| 2021-11-17 | Werner Milton H. | President and CEO | 23,589 0.0935% | $1.97 | $46,558 | -51.43% |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | 13018965 9.3302% | $19.27M | 1 | 0 | |
| Werner Milton H. | President and CEO | 5335433 3.8237% | $7.9M | 4 | 0 | <0.0001% |
| Bellini Roberto | director | 1460000 1.0463% | $2.16M | 1 | 0 | <0.0001% |
| Munshi Amit | director | 365000 0.2616% | $540,200.00 | 1 | 0 | <0.0001% |
| Kush Arvind | director | 145000 0.1039% | $214,600.00 | 1 | 0 | <0.0001% |
| FRATTAROLI JOSEPH | Chief Financial Officer | 48091 0.0345% | $71,174.68 | 1 | 0 | +18.78% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 48 | +106.67% | 52M | +93.77% |
| Decreased Positions | 17 | -37.78% | 394,329 | -0.72% |
| New Positions | 21 | New | 30M | New |
| Sold Out Positions | 2 | Sold Out | 156,339 | Sold Out |
| Total Postitions | 76 | +68.89% | 106M | +93.06% |
| Sands Capital Alternatives, Llc | $21,353.00 | 9.05% | 10.95M | 0 | 0% | 2025-09-30 |
| Soleus Capital Management, L.P. | $12,334.00 | 5.23% | 6.33M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $11,944.00 | 5.06% | 6.13M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $10,572.00 | 4.48% | 5.42M | -10,725 | -0.2% | 2025-09-30 |
| Commodore Capital Lp | $10,525.00 | 4.46% | 5.4M | 0 | 0% | 2025-09-30 |
| Adar1 Capital Management, Llc | $10,233.00 | 4.34% | 5.25M | +125,498 | +2.45% | 2025-09-30 |
| Vanguard Group Inc | $6,383.00 | 2.71% | 3.27M | +48,969 | +1.52% | 2025-09-30 |
| Blackrock, Inc. | $5,997.00 | 2.54% | 3.08M | +347,018 | +12.72% | 2025-09-30 |
| Blackstone Inc. | $5,145.00 | 2.18% | 2.64M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $4,271.00 | 1.81% | 2.19M | 0 | 0% | 2025-09-30 |